Original language | English |
---|---|
Pages (from-to) | 575-578.e9 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 129 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2012 |
Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients. / Li, Xingnan; Ampleford, Elizabeth J.; Howard, Timothy D.; Moore, Wendy C.; Li, Huashi; Busse, William W.; Castro, Mario; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Teague, W. Gerald; Wenzel, Sally E.; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.
In: Journal of Allergy and Clinical Immunology, Vol. 129, No. 2, 02.2012, p. 575-578.e9.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients
AU - Li, Xingnan
AU - Ampleford, Elizabeth J.
AU - Howard, Timothy D.
AU - Moore, Wendy C.
AU - Li, Huashi
AU - Busse, William W.
AU - Castro, Mario
AU - Erzurum, Serpil C.
AU - Fitzpatrick, Anne M.
AU - Gaston, Benjamin
AU - Israel, Elliot
AU - Jarjour, Nizar N.
AU - Teague, W. Gerald
AU - Wenzel, Sally E.
AU - Hawkins, Gregory A.
AU - Bleecker, Eugene R.
AU - Meyers, Deborah A.
N1 - Funding Information: Disclosure of potential conflict of interest: W. W. Busse is on the advisory board for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and the NIH/National Heart, Lung, and Blood Institute (NHLBI) . M. Castro is a consultant and speaker for Asthmatx; is on the advisory board of and speaker for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received grants through his institution from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, Novartis, the NIH , and GlaxoSmithKline; has received royalties from Elsevier; and has received research support from the NIH . S. C. Erzurum has received research support from Asthmatx . B. Gaston is on the advisory board of Respiratory Research, Inc, and Galleon Pharmaceuticals and has received research support from the NIH . N. N. Jarjour has received research support from GlaxoSmithKline, Merck, and Genentech and has provided legal consultation services/expert witness testimony for Genentech and Asthmatx. G. A. Hawkins has received research support from the NIH . The rest of the authors declare that they no relevant conflicts of interest. Funding Information: SARP centers were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762 . Genetic studies for SARP and CSGA were funded by NIH grant HL87665 . The clinical TENOR study was supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation , and the genetic studies were funded by NIH grants HL76285 and HL87665 .
PY - 2012/2
Y1 - 2012/2
UR - http://www.scopus.com/inward/record.url?scp=84856459633&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.09.040
DO - 10.1016/j.jaci.2011.09.040
M3 - Article
C2 - 22070912
AN - SCOPUS:84856459633
VL - 129
SP - 575-578.e9
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 2
ER -